SynthesisJournal of the ASEAN Federation of Endocrine Societies2025
Multiple Therapeutic Applications of Metformin Moving Beyond Its Anti-Diabetic Role: A Systematic Review.
Synthesis in Journal of the ASEAN Federation of Endocrine Societies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Metformin is a commonly used anti-diabetic drug due to its safety, low cost, and strong glucose-lowering effects. Recent research studies have identified novel molecular targets and pathways for metformin, thereby expanding its potential beyond the treatment of Type 2 diabetes. Methodology: This systematic review provides the latest updates on the therapeutic applications of metformin in multiple diseases. This systematic review follows the PRISMA guidelines, focusing on experimental studies systematic reviews and meta-analyses from PubMed, Scopus, Web of Science and Google scholar, the search terms ("Metformin"[MeSH] OR "Metformin") AND ("Cancer" OR "Cardiovascular Disease" OR "Neurodegenerative Disease" OR "Aging") AND ("Therapeutic Use" OR "Non-diabetic"). A comprehensive search yielded numerous studies, from which relevant and up-to-date papers were carefully selected. Results: The review highlights the multifaceted applications of metformin in various diseases. Evidence demonstrates its positive effects on cardiovascular diseases, obesity, different types of cancer, and liver and kidney disorders. These findings suggest that metformin acts through diverse molecular mechanisms, exerting benefits that extend beyond glycemic control. Conclusion: Based on the current literature, metformin exhibits a broad spectrum of therapeutic benefits, extending beyond its primary use in diabetes management. Its role in treating multiple diseases has marked it as a multifaceted agent in modern medicine. Further research is warranted to fully explore its capabilities and optimize its use in different clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.